릴피비린 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "릴피비린" in Korean language version.

refsWebsite

Global rank Korean rank

68^th place

145^th place

3web.archive.org

1^st place

1^st place

447^th place

433^rd place

2clinicaltrials.gov

5,225^th place

4,327^th place

4^th place

4^th place

1medicines.org.uk

3,823^rd place

2,321^st place

low place

low place

2,769^th place

1,748^th place

1retroconference.org

low place

low place

399^th place

141^st place

low place

low place

aidsmap.com (Global: low place; Korean: low place)

“"Eviplera"”.

clinicaltrials.gov (Global: 5,225^th place; Korean: 4,327^th place)

drugs.com (Global: 399^th place; Korean: 141^st place)

“Rilpivirine Monograph for Professionals” (영어). 2021년 5월 19일에 확인함.

europa.eu (Global: 68^th place; Korean: 145^th place)

ema.europa.eu

“Edurant EPAR”. 《European Medicines Agency (EMA)》. 2021년 1월 4일에 확인함.
“Rekambys EPAR”. 《European Medicines Agency (EMA)》. 2020년 10월 13일. 2021년 1월 4일에 확인함.
“European Medicines Agency (EMA)”. 13 October 2020. Retrieved 4 January 2021.
“"First long-acting injectable antiretroviral therapy for HIV recommended approval"”. European Medicines Agency (EMA) (Press release). 16 October 2020. Retrieved 16 October 2020.
“Rekambys: EPAR – public assessment report" (PDF)” (PDF). European Medicines Agency. 2021년 2월 22일.
“"Vocabria: EPAR – Product information"” (PDF).
“"Edurant: EPAR – public assessment report"” (PDF).
“Edurant: EPAR – public assessment report” (PDF). European Medicines Agency. 2021년 1월 4일.
European Medicines Agency (EMA) (16 October 2020. Retrieved 16 October 2020). “"Rekambys: Pending EC decision"”.
European Medicines Agency (EMA) (16 October 2020. Retrieved 16 October 2020.). “"First long-acting injectable antiretroviral therapy for HIV recommended approval"”.

fda.gov (Global: 447^th place; Korean: 433^rd place)

accessdata.fda.gov

“"Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) Tablets"”. U.S. Food and Drug Administration (FDA). 29 November 2016. Retrieved 23 January 2021.
U.S. Food and Drug Administration (FDA). (20 August 2013. Retrieved 23 January 2021.). “"Drug Approval Package: Edurant (rilpivirine) NDA #202022#"”.

fda.gov

“"FDA approves new HIV treatment"”. 2017년 1월 18일에 원본 문서에서 보존된 문서. 2021년 5월 19일에 확인함.

lww.com (Global: 2,769^th place; Korean: 1,748^th place)

journals.lww.com

“"Short-term antiviral activity of TMC278—a novel NNRTI—in treatment-naive HIV-1-infected subjects"”.

medicines.org.uk (Global: 3,823^rd place; Korean: 2,321^st place)

“Edurant 25 mg tablets - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2020년 1월 21일. 2021년 1월 4일에 확인함.

nih.gov (Global: 4^th place; Korean: 4^th place)

dailymed.nlm.nih.gov

“Edurant- rilpivirine hydrochloride tablet, film coated”. 《DailyMed》. 2021년 1월 4일에 확인함.

pubmed.ncbi.nlm.nih.gov

Eur. J. Med. Res. (2007). “"Antiviral drugs in the treatment of AIDS: what is in the pipeline?"”. Stellbrink HJ.

retroconference.org (Global: low place; Korean: low place)

Pozniak A, Morales-Ramirez J, Mohap L 외 (2007년 10월 19일). “"48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB"”. 2008년 6월 26일에 원본 문서에서 보존된 문서. 2021년 5월 19일에 확인함.

tibotec.com (Global: low place; Korean: low place)

“"TMC278 — A new NNRTI"”. 2008-12-20. Retrieved 2010-03-07. 2008년 12월 20일에 원본 문서에서 보존된 문서. 2021년 5월 19일에 확인함.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“"TMC278 — A new NNRTI"”. 2008-12-20. Retrieved 2010-03-07. 2008년 12월 20일에 원본 문서에서 보존된 문서. 2021년 5월 19일에 확인함.
Pozniak A, Morales-Ramirez J, Mohap L 외 (2007년 10월 19일). “"48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB"”. 2008년 6월 26일에 원본 문서에서 보존된 문서. 2021년 5월 19일에 확인함.
“"FDA approves new HIV treatment"”. 2017년 1월 18일에 원본 문서에서 보존된 문서. 2021년 5월 19일에 확인함.